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ABSTRACT 
Friedreich ataxia (FRDA) is an inherited neurodegenerative disorder caused by GAA 
repeat expansion within the FXN gene, leading to epigenetic changes and 
heterochromatin-mediated gene silencing that result in a frataxin protein deficit. 
Histone deacetylase (HDAC) inhibitors, including pimelic o-aminobenzamide 
compounds 106, 109 and 136, have previously been shown to reverse FXN gene 
silencing in short-term studies of FRDA patient cells and a knock-in mouse model, 
but the functional consequences of such therapeutic intervention have thus far not 
been described. We have now investigated the long-term therapeutic effects of 106, 
109 and 136 in our GAA repeat expansion mutation-containing YG8R FRDA mouse 
model. We show that there is no overt toxicity up to 5 months of treatment and there 
is amelioration of the FRDA-like disease phenotype. Thus, while the neurological 
deficits of this model are mild, 109 and 106 both produced an improvement of motor 
coordination, whereas 109 and 136 produced increased locomotor activity. All three 
compounds increased global histone H3 and H4 acetylation of brain tissue, but only 
109 significantly increased acetylation of specific histone residues at the FXN locus. 
Effects on FXN mRNA expression in CNS tissues were modest, but 109 significantly 
increased frataxin protein expression in brain tissue. 109 also produced significant 
increases in brain aconitase enzyme activity, together with reduction of neuronal 
pathology of the dorsal root ganglia (DRG). Overall, these results support further 
assessment of HDAC inhibitors for treatment of Friedreich ataxia. 
 
Keywords: Friedreich ataxia; FRDA, frataxin; trinucleotide repeat; transgenic mouse 
model; histone deacetylase inhibitor; HDAC inhibitor. 
 
3 
 
Introduction 
Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative 
disorder predominantly caused by a homozygous GAA repeat expansion mutation 
within intron 1 of the FXN gene (Campuzano et al., 1996). Normal individuals have 5 
to 30 GAA repeat sequences, whereas affected individuals have from approximately 
70 to more than 1,000 GAA triplets. The effect of the GAA expansion mutation is to 
reduce the production of frataxin (Campuzano et al., 1997), a ubiquitously expressed 
mitochondrial protein that acts in iron-sulphur cluster and heme biosynthesis 
(Pandolfo and Pastore, 2009). Frataxin insufficiency leads to decreased activity of 
iron-sulphur cluster enzymes, such as aconitase and the mitochondrial respiratory 
chain complexes (Bradley et al., 2000), followed by mitochondrial iron accumulation 
and resultant cell death, with the primary sites of pathology being the large sensory 
neurons of the DRG and the dentate nucleus of the cerebellum (Koeppen et al., 2007; 
Koeppen et al., 2009). The outcome is progressive spinocerebellar neurodegeneration, 
causing symptoms of incoordination (“ataxia”), muscle weakness, and sensory loss. 
There is also pathology of non-neuronal tissues, with cardiomyopathy a common 
secondary effect and diabetes found in 10% of FRDA patients (Schulz et al., 2009). 
Affected individuals are confined to a wheelchair within 20 years after the first 
appearance of symptoms, and most commonly die in early adulthood from the 
associated heart disease. Therefore, there is urgent need to develop an effective 
therapy for this lethal disorder.  
Thus far, FRDA clinical trials using antioxidants and iron chelators have 
demonstrated some limited success at ameliorating secondary disease effects (Schulz 
et al., 2009). However, a more effective therapy may be achieved by targeting the 
more immediate effects of the GAA repeat expansion mutation to elevate deficient 
4 
 
frataxin levels. Although the mechanisms by which the GAA repeat expansion leads 
to a frataxin deficit are currently not known, two non-exclusive hypotheses have been 
put forward. Firstly, it has been suggested that the GAA repeat expansion may adopt 
abnormal non-B DNA or DNARNA hybrid triplex structures that interfere with FXN 
gene transcription (Grabczyk et al., 2007; Wells, 2008). Secondly, there is evidence 
that GAA repeat expansions can produce a heterochromatin-mediated gene silencing 
effect (Saveliev et al., 2003), likely acting through epigenetic processes, such as DNA 
methylation and histone modifications. In support of this second hypothesis, recent 
studies of FRDA patient cells and tissues by ourselves and others have identified 
several GAA expansion-specific epigenetic changes (Al-Mahdawi et al., 2008; De 
Biase et al., 2009; Greene et al., 2007; Herman et al., 2006). Thus, GAA repeat 
expansions are associated with: (i) increased DNA methylation in the region of FXN 
intron 1 immediately upstream of the GAA repeat (Al-Mahdawi et al., 2008; Greene 
et al., 2007); (ii) reduced H3K9 acetylation and increased H3K9 and H3K27 
trimethylation at the FXN promoter (Al-Mahdawi et al., 2008; De Biase et al., 2009), 
and (iii) reduced acetylation of several H3 and H4 lysine residues together with 
increased H3K9 di- and trimethylation in both the upstream and downstream GAA 
regions (Al-Mahdawi et al., 2008; Greene et al., 2007; Herman et al., 2006). 
Therefore, there is ample evidence to propose reversal of FXN gene silencing by the 
use of epigenetic-modifying compounds as a potential therapy for FRDA. 
HDAC inhibitors are a structurally diverse group of compounds that have been 
widely used in the treatment of various human cancers (Cang et al., 2009; Monneret, 
2005; Prince et al., 2009). They are generally believed to act by increasing global 
histone acetylation and thereby reactivating epigenetically silenced genes, although 
HDAC inhibitors can also promote acetylation of non-histone proteins (Butler and 
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Bates, 2006). Initial treatment of FRDA lymphoblastoid cells using a panel of 
commercially available HDAC inhibitors revealed that only the benzamide compound 
BML-210 (N
1
-(2-aminophenyl)-N
8
-phenyloctanediamide) produced a significant 
increase of FXN mRNA expression (Herman et al., 2006). Subsequent synthesis of 
analogues of BML-210 identified a pimelic o-aminobenzamide compound, 4b (N
1
-(2-
aminophenyl)-N
7
-phenylheptanediamide), which was shown to act on FRDA primary 
lymphocytes to significantly increase acetylation of H3K14, H4K5 and H4K12 in the 
FXN upstream GAA region and to increase FXN mRNA levels by 2.5-fold (Herman 
et al., 2006). Further development of this family of benzamide HDAC inhibitors 
identified 3 other pimelic o-aminobenzamide compounds, 106 (N
1
-(2-aminophenyl)-
N
7
-p-tolylheptanediamide), 136 (N-(6-(2-amino-4-fluorophenylamino)-6-oxyhexyl)-
4-methylbenzamide) and 109 (N-(6-(2-aminophenylamino)-6-oxyhexyl)-4-
methylbenzamide), which have each undergone investigations to determine 
pharmacokinetic properties, safety and efficacy in short-term treatments of FRDA 
patient cells and mice (Chou et al., 2008; Rai et al., 2010; Rai et al., 2008; Soragni et 
al., 2008; Xu et al., 2009). 106, 136 and 109 all act as slow-on, slow-off, tight binding 
inhibitors of class I HDACs, with a preference for HDAC3 (Chou et al., 2008; Rai et 
al., 2010; Xu et al., 2009). Furthermore, they all produce significant short-term 
increases in H4K5 acetylation and FXN mRNA and frataxin protein expression in 
FRDA primary lymphocytes and brain and heart tissues of FRDA KIKI mice (Rai et 
al., 2010; Rai et al., 2008).  
We have established a GAA repeat expansion mutation-based mouse model of 
FRDA, designated YG8R, by cross breeding YG8 human genomic YAC transgenic 
mice that contain the entire FXN gene and expanded GAA repeats (Al-Mahdawi et al., 
2004) with heterozygous Fxn knockout mice (Cossee et al., 2000). The resulting 
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YG8R mice rescue the embryonic lethality of the Fxn homozygous knockout alleles 
by expressing only human frataxin from the GAA repeat-mutated FXN transgene in a 
mouse frataxin null background (Al-Mahdawi et al., 2006). The YG8R mice exhibit 
an FRDA-like molecular disease phenotype that includes intergenerational and 
somatic instability of the GAA repeat expansion mutation (Al-Mahdawi et al., 2004; 
Clark et al., 2007), together with increased DNA methylation, reduced histone H3 and 
H4 acetylation and increased di- and trimethylated H3K9 at the FXN upstream GAA 
region, when compared with Y47R control transgenic mice that contain the same 
human FXN YAC transgene but with normal-sized GAA repeats (Al-Mahdawi et al., 
2008). Furthermore, YG8R frataxin mRNA levels in brain tissue are reduced to 
approximately 30% when compared with Y47R control transgenic mice (Al-Mahdawi 
et al., 2008). Although the YG8R mice do not show reduction of frataxin mRNA 
levels in brain tissue when compared with wild type mice, frataxin protein levels are 
reduced to approximately 70% that of wild-type mice (Al-Mahdawi et al., 2006). 
YG8R mice are also likely to have impaired function of the human transgene-derived 
frataxin, resulting in deficits that are consistent with FRDA disease, including mildly 
impaired motor coordination ability, reduced aconitase enzyme activity and abnormal 
DRG neuronal pathology (Al-Mahdawi et al., 2006). Therefore, we consider YG8R to 
be a suitable mouse model in which to investigate potential FRDA therapies and we 
now report the effects of prolonged treatment with HDAC inhibitors 106, 136 and 
109. Our results show that each compound is well tolerated during chronic 
subcutaneous dosing for up to 5 months. We detect improvements of behavioural, 
molecular, biochemical and histological measurements, particularly with 109, that are 
consistent with the compounds crossing the blood-brain barrier to ameliorate FRDA-
like disease effects. 
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Materials and methods 
 
Animal procedures 
Genotyping of mice to identify human transgenic GAA sequences and 
endogenous mouse Fxn knockout alleles was performed as previously described 
(Pook et al., 2001). Mice were housed in conventional open cages with Litaspen 
Premium 8/20 bedding, paper wool nesting and standard fun tunnel environmental 
enrichment, with 13 hours light, 11 hours dark, 20-23
o
C and 45-60% humidity. The 
mice were given a diet of SDS RM3 Expanded food pellets and standard drinking 
water. All procedures were carried out in accordance with the UK Home Office 
„Animals (Scientific Procedures) Act 1986‟.  
 
Drug treatment 
HDAC inhibitors 106 (N
1
-(2-aminophenyl)-N
7
-p-tolylheptanediamide), 136 
(N-(6-(2-amino-4-fluorophenylamino)-6-oxyhexyl)-4-methylbenzamide) and 109 (N-
(6-(2-aminophenylamino)-6-oxyhexyl)-4-methylbenzamide) were obtained from 
Repligen Corporation, Waltham, MA, USA, and were synthesized as previously 
described (Rai et al., 2010; Rai et al., 2008). 30 mg/ml 106 was prepared in a vehicle 
solution of 2.5% DMSO, 40% hydroxypropyl-β-cyclodextrin, 140mM Na acetate 
pH5.2, and 10mg/ml 136 and 109 were prepared in a vehicle solution of 20% 
glycerol, 20% PEG400, 20% propylene glycol, 5mM Na acetate pH5.2. Mice were 
given subcutaneous injections of 150mg/kg 106 three times per week for 4.5 months, 
or 50mg/kg 136 or 100mg/kg 109 five times per week for 5 months, followed by 
culling for tissue collection 24 hours after the final injection. 
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Behavioural assessments 
Rotarod performances of YG8R and C57BL/6J wild-type mice were assessed 
using a Ugo Basile 7650 accelerating rotarod treadmill and open field locomotor 
activity was assessed using a gridded perspex box in light room conditions, as 
previously described (Al-Mahdawi et al., 2006). Ambulatory distance and vertical 
counts were measured over 2 minute periods in the dark and repeated four times for 
each mouse using a beam breaker activity monitor (Medical Devices, Inc.). For final 
analysis, the fold change in mean performance time for each group of mice was 
calculated and compared with the original mean performance time.  
 
Quantitative reverse transcriptase PCR 
Total RNA was isolated from snap frozen tissues by homogenization with 
Trizol (Invitrogen) and cDNA was then prepared by using AMV reverse transcriptase 
(Invitrogen) with oligo-dT primers. Levels of human transgenic FXN or endogenous 
Fxn mRNA expression were assessed by quantitative RT-PCR using an ABI7900 
sequencer and SYBR
®
 Green (Applied Biosystems) with the following primers that 
equally amplify human and mouse sequences: FRT-I 5‟-
TTGAAGACCTTGCAGACAAG-3‟ and RRT-II 5‟-
AGCCAGATTTGCTTGTTTGG-3‟. Mouse Gapdh RT-PCR primers used for 
normalisation were as follows: GapdhmF 5‟-ACCCAGAAGACTGTGGATGG-3‟ 
and GapdhmR 5‟-GGATGCAGGGATGATGTTCT-3‟.  
Gapdh mRNA expression was similarly quantified using GapdhmF and GapdhmR 
primers and using mouse Rer1 RT-PCR primers for normalisation, as follows: RER1-
F: 5‟-CCACCTAAACCTTTTCATTGCG-3‟ and RER1-R: 5‟-
TTTGTAGCTGCGTGCCAAAAT-3‟. 
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Reactions were carried out in triplicate for each biological sample (n=4).  
 
Western blot analysis 
Protein lysates were obtained from snap frozen brain tissues, and frataxin 
western blot analysis was carried out as previously described (Pook et al., 2001), 
using an anti-frataxin rabbit polyclonal antibody (Santa Cruz 25820). Histone H3 and 
H4 acetylation levels were determined by western blot analysis using anti-acetyl-
Histone H3 (Upstate 06-599) and anti-acetyl-Histone H4 (Upstate 06-866) antibodies, 
respectively. In all cases, normalisation was carried out using a rat anti--tubulin 
monoclonal antibody (Abcam AB6160). Densitometry was carried out using UN-
SCAN-IT software (Silk Scientific Corporation) and in all cases n=4. 
 
ChIP analysis 
ChIP analysis was carried out by initial cross-linking of DNA and protein by 
formaldehyde treatment of homogenised frozen tissue samples. DNA was then 
sheared by sonication, followed by immunoprecipitation with commercially available 
anti-acetylated histone H3 and H4 antibodies: H3K9ac, H4K5ac and H4K12ac 
(Upstate). For each experiment, normal rabbit serum (SIGMA) was used as a minus 
antibody immunoprecipitation control. After reversal of cross-linking, quantitative 
PCR amplification of the resultant co-immunoprecipitated DNA was carried out with 
SYBR
®
 Green in an ABI7400 sequencer (Applied Biosystems) using three sets of 
FXN primers (Pro, Up and Down) and mouse Gapdh primers, as previously described 
(Al-Mahdawi et al., 2008; Herman et al., 2006). Each tissue sample was subjected to 
two independent ChIP procedures, followed by triplicate quantitative PCR analysis. 
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Aconitase activity assay 
Aconitase activities were determined by homogenisation of mouse brain 
tissues on ice at 10% w/v in CellLytic MT Mammalian Tissue Lysis/Extraction buffer 
(SIGMA, C3228), followed by centrifugation at 800 x g for 10 minutes at 4
o
C. 50ul 
of tissue lysates were then added to 200ul of substrate mix (50mM Tris/HCl pH7.4, 
0.4mM NADP, 5mM Na citrate, 0.6mM MgCl2, 0.1% (v/v) Triton X-100 and 1U 
isocitrate dehydrogenase) and the reactions were incubated at 37
o
C for 15 minutes, 
followed by spectrophotometric absorbance measurements every minute for 15 
minutes at 340nm 37
o
C to determine the reaction slope. Aconitase activities of mouse 
brain tissues were then normalised to citrate synthase activities, which were 
determined using a citrate synthase assay kit (SIGMA, CS0720).  
 
DRG histology 
Histological preparations of mouse DRG were carried out by dissection of 
paraformaldehyde-fixed intact lumbar vertebrae, followed by decalcification 
treatment in Hillman and Lee‟s EDTA daily for 5 days. Tissues were then embedded 
in paraffin wax, sectioned by standard methods, deparaffinised with IMS and 
Histoclear (National Diagnostics) and slides were stained with hematoxylin and eosin. 
 
Statistical analysis 
Body weight, rotarod performance, locomotor activity, ambulatory distance 
and vertical counts beam-breaker data were analysed by two-way ANOVA for 
genotype (YG8R or wild-type) and time (age of mice) to detect disease-like effects 
and for treatment (HDAC inhibitor or vehicle) and time (age of mice) to detect drug 
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effects. All other data were analysed by the Student‟s t test, with a significance value 
set at p < 0.05. 
 
Results 
HDAC inhibitors 106, 136 and 109 are well tolerated in chronic dosing of mice 
HDAC inhibitors 106, 136 and 109 have previously been administered 
subcutaneously to a separate GAA knock-in mouse model (KIKI mice, where GAA 
repeats have been introduced into the mouse frataxin gene) daily for a period of 3 
days, without any toxic effects (Rai et al., 2010; Rai et al., 2008). We wanted to 
determine if this lack of acute toxicity could be maintained throughout long-term 
dosing regimes. We initially treated one group of fifteen 3- to 4-month old YG8R 
mice with 150mg/kg 106 by subcutaneous injection 3 times per week for a period of 
4.5 months, together with an age-and sex-matched YG8R control group treated with 
vehicle only. We subsequently treated three groups of twenty age- and sex-matched 3- 
to 4-month old YG8R mice with either 50mg/kg 136, 100mg/kg 109 or vehicle-only 
by subcutaneous injection 5 times per week for a period of 5 months. At the same 
time, we similarly treated three groups of ten age-and sex-matched 3- to 4-month old 
wild-type (C57BL/6J) mice (YG8R mice are in a C57BL/6J genetic background and 
Y47R control transgenic mice were not available for this study) with either 50mg/kg 
136, 100mg/kg 109 or vehicle-only by subcutaneous injection 5 times per week for a 
period of 5 months.  
The long-term administrations of 106, 136 and 109 were well tolerated and no 
toxicity was generally observed in the mice throughout the entire period of study. 
However, one 136-treated YG8R mouse died from an unknown cause after 4 months 
and one 109-treated wild-type mouse showed a failure to thrive after 2 months and 
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was therefore culled. Analysis of body weight over time by two-way ANOVA 
detected a non-significant (F = 2.9, p = 0.086) reduction in the weight gain of YG8R 
mice compared with wild-type mice. This mild detrimental phenotype remained 
unaffected by prolonged treatment with 109 (F = 1.28, p = 0.25), but treatment with 
106 and 136 resulted in significant further reductions in weight gain (F = 13.5, p < 
0.001 and F = 5.0, p < 0.05, respectively) (Fig. S1), indicating that 109 is the best 
tolerated of the three compounds under the dosing conditions tested. 
 
106 and 109 improve motor coordination of YG8R FRDA mice. 
Motor coordination was assessed by change in performance on a rotarod 
treadmill at monthly time points throughout the treatment periods. An initial 
comparison of vehicle-treated YG8R and wild-type mice revealed a gender-specific 
phenotype, which has not previously been investigated or reported. Thus, no 
significant difference in rotarod performance was noted when both male and female 
values were taken together (Fig. 1A) or when male values were considered alone (Fig. 
1B). However, analysis of female values alone revealed a significantly reduced 
rotarod performance (F = 35.9, p < 0.001) in YG8R mice (Fig. 1C). With this in 
mind, only the rotarod performances of female mice were taken into account when 
determining any effect of the HDAC inhibitors on motor coordination. Both 106 and 
109 treatments were found to improve the rotarod performances of YG8R female 
mice (F = 44.2, p < 0.001 and F = 20.0, p < 0.001, respectively) (Figs. 1D and S1D), 
while 136 treatment showed no effect. Furthermore, the rotarod improvement 
achieved by 109 treatment appeared to be specific for YG8R mice, since no effect 
was seen with 109 treatment of wild-type female mice (Fig. 1D). 
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136 and 109 improve locomotor activity of YG8R FRDA mice. 
Several parameters were used to measure locomotor activity of mice. 
However, unlike the analysis of motor coordination, no gender-specific YG8R 
phenotype was observed and therefore the combined male and female data are 
presented.  Firstly, the open field activity of 106- and 136-treated YG8R mice 
compared with vehicle-treated YG8R mice was assessed by determining the distance 
moved within a gridded perspex box under normal light conditions, as previously 
described (Al-Mahdawi et al., 2006). 106 treatment had no effect on activity, whereas 
136 treatment significantly increased activity in YG8R mice (F = 17.7, p < 0.001) 
(Fig. S1E). Secondly, for the study of 136- and 109-treated YG8R and wild-type 
mice, beam-breaker activity monitor apparatus was used to measure (i) the total 
horizontal distance moved („ambulatory distance‟) and (ii) a count of the vertical 
movements due to rearing on hind limbs („vertical counts‟) within a 2-minute period 
under dark conditions. Initial analysis by two-way ANOVA detected a significant 
ambulatory distance disease-like phenotype of YG8R mice compared with wild-type 
mice (F = 6.0, p < 0.05). Subsequent treatments with 136 and 109 both produced 
significant increases in the ambulatory distance of YG8R mice towards wild-type 
values (F = 13.6, p < 0.001 and F = 22.3, p < 0.001, respectively) (Fig. 2A and B). 
These increases were specific for YG8R mice, since 136 produced a non-significant 
decrease (F = 0.34, p = 0.56), while 109 produced a non-significant increase (F = 
1.92, p = 0.167), in the ambulatory distance of wild-type mice (Figs. 2A and B). Two-
way ANOVA analysis also detected a significant vertical counts disease-like 
phenotype of YG8R mice compared with wild-type mice (F = 24.5, p < 0.001). Only 
136 treatment caused a significant increase in the vertical counts of YG8R mice 
compared to vehicle-treated controls (F = 67.4, p < 0.001) (Fig. 2C), and this effect 
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was specific for YG8R, because the values were significantly decreased in 136-
treated wild-type mice (F = 8.6, p < 0.01). 109 treatment was shown to have no effect 
(F = 1.7, p = 0.19) (Fig. 2D).  
 
106, 136 and 109 increase general histone acetylation levels in the brain 
To examine the effects of prolonged dosing of 106, 136 and 109 on general 
histone acetylation within the brain tissue of YG8R and wild-type mice, acetylated H3 
and acetylated H4 levels were determined by western blotting analysis (Fig. 3). No 
differences in either acetylated H3 or acetylated H4 levels were detected between 
wild-type and YG8R mice. However, increases in both acetylated H3 and acetylated 
H4 levels were detected in YG8R mice treated with all three HDAC inhibitors 
compared to vehicle-treated controls, and similar increases were seen in HDAC 
inhibitor-treated wild-type mice. Compound 109 exhibited a more pronounced effect 
on acetylated H3 levels, which were increased by 1.5-fold, although not to statistical 
significance (Fig. 3C). In contrast, 106 and 136 had more prominent effects on 
acetylated H4 levels, each producing significant 1.4-fold increases (p < 0.05 and p < 
0.01, respectively) (Fig. 3D).  
 
109 increases acetylated H3K9, H4K5 and H4K12 within the FXN transgene and the 
endogenous mouse Gapdh gene in YG8R brain tissue. 
We have previously detected comparatively reduced levels of acetylated H3 
and H4 histone residues in brain tissue of expanded GAA repeat YG8 transgenic mice 
compared with normal-sized GAA repeat Y47 transgenic mice by performing 
chromatin immunoprecipitation (ChIP) analysis at three regions of the FXN gene: the 
promoter, upstream of the GAA repeat and downstream of the GAA repeat (Al-
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Mahdawi et al., 2008). Therefore, to investigate HDAC inhibitor effects after 
prolonged treatment of YG8R mice, we performed ChIP analysis of acetylated H3K9, 
H4K5 and H4K12 residues at the same three FXN regions, comparing results from 
HDAC inhibitor-treated and vehicle-treated YG8R mouse brain tissues. We chose to 
examine H3K9 and H4K12 because these residues previously showed the greatest 
decreases in acetylation in YG8 transgenic mice, and H4K5 was chosen because this 
residue is known to be the most preferentially modified by HDAC3, the principle 
HDAC target of the pimelic o-aminobenzamide HDAC inhibitors (Chou et al., 2008; 
Xu et al., 2009). Treatment with 106 produced little effect, although non-significant 
1.6-fold and 2.3-fold increases of acetylated H4K5 were observed in the FXN 
promoter and downstream GAA regions, respectively (Fig. 4A-C). Similarly, 
treatment with 136 showed no effect (Fig. 4D-F). However, 109 treatment produced 
striking increases in each of the three acetylated H3K9, H4K5 and H4K12 residues in 
all three regions of the FXN locus, with the most statistically significant increases 
found at H3K9 and H4K5 residues. The largest increases, measured by fold-change, 
were detected for the acetylated H3K9 residue, with 6-fold, 8-fold and 4.5-fold 
increases at the promoter, upstream GAA and downstream GAA regions, respectively 
(Fig. 4G-I). However, the most statistically significant increases were observed for 
the acetylated H4K5 residue at the promoter and upstream GAA regions (Fig. 4G-H). 
At the same time, as a control experiment, we investigated 109 effects on acetylation 
of H3K9, H4K5 and H4K12 in the endogenous mouse Gapdh gene, using the same 
mouse brain tissues. As with the FXN gene, 109 produced increases in all three 
acetylated histone residues, with significant 8-fold and 1.8-fold increases in H3K9 
and H4K5, respectively (Fig. S2A).  
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FXN mRNA levels in CNS tissues are not significantly altered by prolonged 106, 136 
or 109 treatment. 
To investigate if the increased acetylation that we found in FXN histone 
residues was reflected by changes of FXN transcription, we determined FXN mRNA 
levels in brain and other CNS tissues by quantitative RT-PCR, comparing HDAC 
inhibitor-treated and vehicle-treated YG8R and wild-type samples. Surprisingly, no 
substantial increases in FXN expression were detected following any of the three 
HDAC inhibitor treatments (Figs. S3 and S4). Some modest increases of FXN 
expression were detected, particularly in spinal cord samples, but none of the changes 
were statistically significant. However, the relative FXN expression levels in 136- and 
109-treated tissues, compared with vehicle-treated tissues, were consistently higher in 
YG8R mice than in WT mice, suggesting some element of specificity towards 
increasing FXN expression in the transgenic FRDA mouse model (Fig. S3). As our 
ChIP experiments had also revealed a significant effect of 109 on acetylated H3 and 
H4 histone residues within the endogenous Gapdh gene, we also assessed brain 
Gapdh mRNA expression levels, but detected no significant changes (Fig. S2B). 
 
109 increases frataxin protein expression in the brain of YG8R FRDA mice 
The same brain tissue samples that had been used to determine FXN 
expression levels were also used to assess comparative levels of frataxin protein 
expression by western blotting analysis (Fig. 5A). Modest 1.6-fold and 2-fold 
increases were seen in 106- and 136-treated YG8R mice, respectively, compared with 
vehicle-treated YG8R mice. However, 109-treated YG8R mice revealed a much more 
significant 2.6-fold increase in frataxin expression when compared with vehicle-
treated YG8R mice (p < 0.05) (Fig. 5B). 1.3-fold and 1.5-fold increases in 
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endogenous mouse frataxin levels were also seen in 136- and 109-treated wild-type 
mice, respectively, suggesting a minor generalized frataxin-increasing effect of these 
drugs, although the increases were not statistically significant (Fig.6). 
 
109 increases aconitase enzyme activity within YG8R mouse brain tissue 
A consistently observed effect of the frataxin deficit in FRDA patients, FRDA 
mouse models and yeast models is a reduction in activity of the iron-sulphur cluster 
containing enzyme aconitase (Bradley et al., 2000; Puccio et al., 2001; Rotig et al., 
1997). We have also previously detected reduced levels of aconitase activity in heart 
tissue from our YG8R mice (Al-Mahdawi et al., 2006). Therefore, we were interested 
to determine whether aconitase activity was also reduced in YG8R brain tissue and 
whether such activity could be influenced by HDAC inhibitor treatment. Our analysis 
shows that there is indeed a significant reduction in YG8R brain aconitase activity to 
17% of wild-type levels (p < 0.001) (Fig. 7). This reduced aconitase activity was 
subsequently increased 1.4-fold by treatment with 136. However, a much more 
significant 4-fold increase occurred with 109 treatment (p < 0.001), returning the 
aconitase activity substantially towards wild-type levels.  
   
109 ameliorates DRG neuronal pathology 
We initially confirmed the presence of vacuolar pathology within the large 
neuronal cell bodies of lumbar DRG as a disease phenotype within the vehicle-treated 
YG8R mice, as we have previously described (Al-Mahdawi et al., 2006) (Fig.8A). 
Quantification of this vacuolar pathology was then performed by calculating the 
number of vacuole-containing neuronal cells as a percentage of total neuronal cells 
within the DRG sections, resulting in a value of 17.5% for YG8R mice, compared 
18 
 
with only 0.9% for wild-type mice. 136 treatment was found to produce a small 
reduction in the level of DRG pathology, with the vacuole count reaching a value of 
13.9% (p = 0.06) (Fig. 8C). However, 109 treatment produced a much more 
significant reduction in DRG pathology (Fig. 8B), with the vacuole count reaching a 
value of 4.7% (p < 0.001) (Fig. 8C), thus indicating substantial amelioration of the 
disease-like phenotype.   
 
Discussion 
The recent understanding that FRDA disease pathogenesis involves GAA 
expansion-induced histone deacetylation of the FXN gene has now led to the proposed 
use of HDAC inhibitors for FRDA therapy (Gottesfeld and Pandolfo, 2009). Initial 
short-term dosing studies with the pimelic o-aminobenzamide HDAC inhibitors 106, 
109 and 136 have demonstrated efficacy at up-regulating frataxin expression in 
FRDA cells and KIKI mouse model tissues, while exhibiting minimal toxicity (Chou 
et al., 2008; Herman et al., 2006; Rai et al., 2010; Rai et al., 2008; Soragni et al., 
2008). In this present study, we investigated the chronic dosing effects of 106, 109 
and 136 in our YG8R FRDA mouse model. We report for the first time that prolonged 
subcutaneous administrations of 106, 109 and 136 are all well tolerated in mice at the 
tested doses, concurring with a recent long-term study of the related HDAC inhibitor 
4b, which demonstrated amelioration of the Huntington disease phenotype in R6/2 
mice without any discernable toxicity (Thomas et al., 2008). Furthermore, we report 
treatment-induced increases of acetylated histones and frataxin expression levels in 
YG8R mouse brain, demonstrating that 106, 109 and 136 can each cross the blood-
brain barrier to exert HDAC inhibitory effects, in agreement with previous short-term 
KIKI mouse studies (Rai et al., 2010; Rai et al., 2008).  
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The HDAC inhibitor treatments did not elicit any dramatic changes in the 
behaviour deficits of YG8R mice, but modest changes were moved in the improved 
direction by drug treatment, including improved motor coordination with 106 and 109 
and increased locomotor activity with 109 and 136. Such differential behavioural 
effects may be due to differences in HDAC inhibitor potency, specificity, tissue 
distribution and effectiveness at crossing the blood-brain barrier. For example, 109, 
which elicited improvements in both behavioural measurements, has been reported to 
exhibit selectivity for HDAC3, but retains the most potency for HDAC1 and HDAC2 
among these three pimelic o-aminobenzamide compounds (Rai et al., 2010).    
 Our results of the treatment effects on histone acetylation at the FXN locus by 
ChIP analysis of brain tissue are in general agreement with previous studies, but 
substantially extend these studies and, as a consequence, provide further evidence for 
the greater potency of 109 compared with 106 or 136. Thus, we have shown that 109 
treatment significantly increases acetylation of H4K5 at the FXN upstream GAA 
region, while 136 treatment has little effect, as similarly described for studies of 
FRDA patient PBMCs and KIKI mouse brain tissues (Rai et al., 2010). However, we 
did not detect any 106-induced increase in acetylation of H4K5 at the FXN upstream 
GAA region, contrary to the 106 effect reported for the KIKI mouse (Rai et al., 2008). 
This discrepancy is most likely due to the different frataxin intron 1 sequences, 
including gene regulatory sequences, which have been studied in the two mouse 
models; the YG8R mouse has human FXN transgenic sequence, while the KIKI 
mouse has murine Fxn sequence. Our study is the first study to report any treatment 
effects of 106, 109 or 136 on the FXN upstream GAA region acetylation status of 
residues H3K9 and H4K12; the two histone residues that show the greatest 
deacetylation in FRDA disease (Al-Mahdawi et al., 2008; Herman et al., 2006; 
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Soragni et al., 2008). Significant increases in acetylation of H3K9 were identified 
only with 109 treatment. In contrast, 106 and 136 had no effect, as previously 
described for the related HDAC inhibitor 4b that similarly did not induce any H3K9 
acetylation changes in the upstream GAA region of human FRDA lymphoblastoid 
cells, but rather preferentially increase acetylation of H3K14 and H4K5 (Herman et 
al., 2006). Our study also detected treatment effects of HDAC inhibitors on histone 
acetylation at the FXN promoter and downstream GAA regions. We identified modest 
106-induced increases in acetylation of H4K5 in both regions and modest increases in 
acetylation of H4K12 in the FXN promoter after treatment with all three compounds. 
However, the most significant changes that we detected were 109-induced increases 
in H3K9 and H4K5 acetylation. 
 Despite the marked 109-induced increases that we detected in acetylated H3 
and H4 residues at the FXN locus in brain tissues of YG8R mice, we did not find any 
corresponding increase in brain FXN mRNA expression, but we did detect a 
significant 2.6-fold increase in frataxin protein expression. Differential timings of 
frataxin mRNA and protein expression could well account for this apparent 
discrepancy or possibly dose levels and dose frequency did not achieve maximal 
exposure and efficacy for each compound. Moreover, we cannot rule out the 
possibility of 109-induced post-transcriptional effects on frataxin expression, such as 
increased frataxin protein stability, as suggested by our detection of small increases in 
endogenous mouse frataxin in HDAC inhibitor-treated wild-type mice as well as the 
more significant increase of human transgenic frataxin in the 109-treated YG8R mice. 
HDAC inhibitors have been shown to change the transcription of many genes 
(Drummond et al., 2005; Rai et al., 2008; Reid et al., 2005; Thomas et al., 2008) and 
some gene expression changes may result in enhanced protein stability, as described 
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in one recent study (Garbes et al., 2009). A similar finding to ours has also been 
reported for the potential FRDA therapeutic compound rhuEPO, where treatment of 
primary FRDA fibroblasts produced up to 2-fold increases in frataxin protein levels 
without any changes in FXN mRNA expression (Acquaviva et al., 2008). The authors 
of this study similarly hypothesised that rhuEPO may stabilize frataxin protein by an 
as yet unknown mechanism. More extensive studies will therefore be necessary to 
determine the mechanism(s) whereby the pimelic o-aminobenzamide HDAC 
inhibitors increase frataxin protein levels. Interestingly, one recent study has 
identified lysine residue 147 to play a critical role in frataxin ubiquitination and 
degradation (Rufini et al., 2011). Therefore, if acetylation of lysine 147 also occurs as 
a competing post-translational modification of frataxin, or indeed if any of the other 
12 frataxin lysine residues prove to be acetylated, HDAC inhibitors could potentially 
exert an effect of promoting frataxin protein stability. 
 Aconitase is an Fe-S-containing enzyme that exists in both mitochondrial and 
cytosolic forms, and a deficit in aconitase activity has previously been identified as a 
major effect of decreased frataxin in FRDA patients, mouse models and yeast models 
(Al-Mahdawi et al., 2006; Bradley et al., 2000; Puccio et al., 2001; Rotig et al., 1997). 
Thus, aconitase activity can be considered a suitable biomarker of FRDA disease. The 
substantial deficit of aconitase activity that we identified in the brain tissue of our 
YG8R mouse (14% of wild-type) is similar to deficits that have been reported for 
human tissues (Bradley et al., 2000), but perhaps more substantial than may have 
been expected considering the comparatively mild degree of brain frataxin protein 
reduction in this mouse model (70% of wild-type) (Al-Mahdawi et al., 2006). 
However, it is very likely that the transgenic human frataxin protein produced within 
the YG8R mouse will not function as effectively as endogenous mouse frataxin 
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protein due to amino acid sequence differences, thereby compounding the frataxin 
deficit and hence the aconitase deficit. Most interestingly, after treatment with HDAC 
inhibitors, the best improvement in aconitase activity was found to be with 109, the 
HDAC inhibitor that produced the most significant changes in histone acetylation, 
together with the largest subsequent increases in frataxin expression.  
 Degeneration of the large sensory neurons within the DRG has long been 
known as a prominent feature of FRDA disease (Koeppen et al., 2009), and more 
recently the formation of pathological vacuoles within these particular cells has also 
been reported in several FRDA mouse models (Al-Mahdawi et al., 2006; Puccio et al., 
2001; Simon et al., 2004). Using the occurrence of DRG vacuoles as a marker of 
FRDA disease pathology in our YG8R mice, we have shown that, as with restoration 
of the aconitase deficit, the HDAC inhibitor that produced the most significant 
improvement in DRG neuronal cell pathology is 109, the HDAC inhibitor that 
produced the most significant increase in frataxin expression. This suggests that 109 
may be exerting beneficial effects on both aconitase activity and neuronal pathology 
as a direct consequence of its ability to increase frataxin protein expression. However, 
it is also possible that some of the amelioration of neuronal pathology is due to an 
additional more general neuroprotective effect of 109, as previously described for the 
effect of HDAC inhibitor 4b on the R6/2 HD mouse model (Thomas et al., 2008). 
Therefore, future microarray gene expression analysis of 109-treated mouse tissue 
would be useful to determine potential upregulation of neuroprotective genes by 109 
treatment. 
 
Conclusions 
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We have shown that prolonged treatment with each of the three HDAC 
inhibitors, 106, 136 and 109, can ameliorate FRDA disease-like effects to some 
extent, and therefore our studies are supportive of advancing HDAC inhibitors for 
treating FRDA. Furthermore, 109 clearly emerges as a lead drug candidate due to its 
ability to increase brain frataxin protein and aconitase activity and reduce DRG 
neuronal pathology in our FRDA mouse model. These beneficial effects are also 
likely to account for the modest improvements in motor coordination performance 
and locomotor activity that we observed with 109 treatment.  However, the 
behavioural deficits of the YG8R mouse model are still rather mild and, therefore, by 
exploiting the unstable nature of the GAA repeat mutation, we are currently 
developing a larger GAA repeat-based FRDA mouse model with more substantial 
reduction in FXN expression and a more severe behavioural phenotype that would be 
beneficial to future drug testing. It may also be useful to investigate the more global 
effects of prolonged 109 treatment by performing microarray gene expression 
profiling of treated YG8R mice, in a similar manner to studies of the related HDAC 
inhibitors 4b and 106 that have each identified expression changes in only a limited 
number of genes (Rai et al., 2008; Thomas et al., 2008). Several HDAC inhibitors 
have now been evaluated for the treatment of a variety of genetic disorders, such as 
spinal muscular atrophy (SMA) (Garbes et al., 2009; Hahnen et al., 2006; Kernochan 
et al., 2005; Riessland et al., 2006), Huntington disease (Butler and Bates, 2006; 
Hockly et al., 2003; Thomas et al., 2008), cardiac hypertrophy (Antos et al., 2003) 
and cystic fibrosis (Hutt et al.). To add to this list, we have now shown that the 
pimelic o-aminobenzamide compound 109 is safe and effective at up-regulating 
frataxin expression in prolonged treatment of an FRDA mouse model. These studies 
support continued evaluation of HDAC inhibitors to treat Friedreich ataxia. 
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Figure legends 
Fig.1. Motor coordination analysis. Relative rotarod performances are shown for 
vehicle-treated YG8R FRDA mice (red) and wild-type (WT) mice (blue) as fold-
changes over a 5-month time period. (A) Combined male and female values (YG8R 
n=20, WT n=10), (B) male values only (YG8R n=10, WT n=5), and (C) female 
values only (YG8R n=10, WT n=5) are shown. (D) Values for 109-treated YG8R 
FRDA mice (purple) and wild-type (WT) mice (green) are shown together with 
vehicle-treated groups (YG8R n=10, WT n=5). Error bars represent s.e.m. 
 
Fig. 2. Beam-breaker behaviour analysis. Relative ambulatory distance (A, B) and 
vertical counts (C, D) are shown as fold changes for vehicle-treated groups of YG8R 
FRDA mice (red) and wild-type (WT) mice (blue) over a 5-month time period. (A) 
and (C) show 136-treated YG8R FRDA mice (purple) and wild-type (WT) mice 
(green). (B) and (D) show 109-treated YG8R FRDA mice (purple) and wild-type 
(WT) mice (green). (YG8R n=20, WT n=10). Error bars represent s.e.m.    
 
Fig. 3. General H3 and H4 acetylation levels in YG8R brain tissues. Western blots 
showing (A) acetylated H3 histones (H3ac) and (B) acetylated H4 histones (H4ac) 
from vehicle (v)-, 136- and 109-treated YG8R mouse brain samples, together with -
tubulin controls. Densitometry calculations of acetylated H3 histones (C) and 
acetylated H4 histones (D) are shown for vehicle-treated wild-type (WT) mice, and 
vehicle-, 106, 136- and 109-treated YG8R mouse brain samples. Values are shown 
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relative to the vehicle-treated WT mouse value. In all cases n=4 and error bars 
represent s.e.m. * p < 0.05, ** p < 0.01.   
 
Fig. 4. ChIP analysis of acetylated H3K9, H4K5 and H4K12 residues within the FXN 
locus of HDAC inhibitor- and vehicle-treated YG8R brain tissues. ChIP quantitative 
PCR results for H3K9ac, H4K5ac and H4K12ac residues within the transgenic FXN 
promoter (A, D, G), upstream GAA region (B, E, H) and downstream GAA region 
(C, F, I) of mouse brain tissue are represented as relative recovery (%), which was 
calculated as the amount of immunoprecipitated DNA compared to input DNA, 
subtracting the – Ab background value. The effects of treatment with 106 (A-C, dark 
blue), 136 (D-F, red) and 109 (G-I, green) are shown in comparison to vehicle-
treatments (light blue). n=3-6 and error bars represent s.e.m. * p < 0.05, ** p < 0.01, 
*** p < 0.001. 
 
Fig. 5. Frataxin protein levels in YG8R brain tissues. (A) Representative western blot 
showing frataxin protein expression, together with -tubulin controls, from vehicle 
(v)- and 109-treated YG8R mouse brain tissues. (B) Densitometry calculations of 
frataxin levels are shown for vehicle-, 106-, 136- and 109-treated YG8R mouse brain 
samples. Values are shown relative to the vehicle-treated YG8R mouse value. In all 
cases n=4 and error bars represent s.e.m. * p < 0.05. 
 
Fig. 6. Frataxin protein levels in wild-type mouse brain tissues. (A) Western blot 
showing frataxin protein expression, together with -tubulin controls, from vehicle 
(v)-, 109- and 136-treated wild-type mouse brain tissues. (B) Densitometry 
calculations of frataxin levels are shown for vehicle-, 136- and 109-treated wild-type 
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(WT) mouse brain samples. Values are shown relative to the vehicle-treated WT 
mouse value and increases were not statistically significant. In all cases n=4 and error 
bars represent s.e.m. 
 
Fig. 7. Aconitase activity of YG8R brain tissues. Aconitase activities for vehicle-
treated wild-type (WT) mice, and vehicle-, 136- and 109-treated YG8R mouse brain 
samples are shown as ratios of the corresponding citrate synthase activity and relative 
to the vehicle-treated WT mouse value set at 100%. n=3-8 and error bars represent 
s.e.m. ** p < 0.01, *** p < 0.001. 
 
Fig. 8. DRG neuronal pathology: (A) Representative H&E-stained histology sections 
of lumber DRG from (A) vehicle-treated and (B) 109-treated YG8R mice. Vacuolar 
pathology of neuronal cell bodies, which is present only in the vehicle-treated section 
(A), is indicated by the arrows. Original magnification = 400X. (C) Graphic 
representation showing the degree of DRG histopathology in vehicle-treated wild-
type (WT) and vehicle-, 136- and 109-treated YG8R mice, calculated as the 
percentage of neurons containing vacuoles compared to the total number of neurons. 
In all cases n=16 and error bars represent s.e.m. *** p < 0.001. 
 
Fig. S1. Weight and behavioural analysis. (A-C) Fold changes in body weights are 
shown for vehicle-treated YG8R (red) and wild-type (WT) (blue) mice and HDAC 
inhibitor-treated YG8R (purple) and wild-type (WT) (green) mice over a 5-month 
time period. (A) 106 (n=15), (B) 136 (YG8R n=20, WT n=10) and (C) 109 (YG8R 
n=20, WT n=10). (D) Relative rotarod performances of 106-treated (blue) and 
vehicle-treated (red) YG8R FRDA mice (n=15). (E) Relative open field locomotor 
32 
 
activities of 136-treated (blue) and vehicle-treated (red) groups of YG8R FRDA mice 
(n=20). Error bars represent s.e.m. 
 
Fig. S2. Gapdh ChIP and mRNA expression levels. (A) ChIP analysis of acetylated 
H3K9, H4K5 and H4K12 residues within the endogenous mouse Gapdh gene of 109- 
and vehicle-treated YG8R mouse brain tissues are represented as relative recovery 
(%), which was calculated as the amount of immunoprecipitated DNA compared with 
input DNA, subtracting the – Ab background value (n=6). (B) Relative Gapdh mRNA 
expression of YG8R mouse brain tissue, compared with a vehicle-treated control 
value set at 100% (n=3). Error bars represent s.e.m. * p < 0.05, *** p < 0.001. 
 
Fig. S3. Relative FXN mRNA levels in HDAC inhibitor-treated YG8R and wild-type 
brain tissues. Relative FXN mRNA expression levels in the brain, spinal cord, DRG 
and cerebellum of YG8R mice (A, B) and wild-type mice (C, D) are shown after 
treatment with 136 (A and C) and 109 (B and D), compared with corresponding 
vehicle-treated controls set at 100%. In all cases n=4.  
 
Fig. S4. FXN mRNA levels in 106-treated brain. Relative FXN mRNA expression 
levels in the brain of 106-treated YG8R mice are shown compared with vehicle-
treated controls set at 100% (n=4). Error bars represent s.e.m. 
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